The incidences of nosocomial infections are varied in different studies, and the crude mortality is high, particularly for intensive-care unit (ICU) patients. (1,2) 
Introduction:
The incidences of nosocomial infections are varied in different studies, and the crude mortality is high, particularly for intensive-care unit (ICU) patients.
(1,2) The rates of antimicrobial resistance among pathogens causing health care-associated infections are increasing, and the main mechanisms that must be submitted to surveillance and accurate diagnosis are ESBL, AmpC and carbapenem resistance in gram negative bacilli, and MRSA and VRE in gram positive cocci.
(3)
Aim of the work
The aim of this study was to determine the incidence of the gram negative and gram positive resistance among nosocomial pathogens, to assess the abilities of phenotypic methods (diffusion based methods) to detect different resistant patterns in relation to MIC profiles tested by the Sensititre automated system and to guide antimicrobial therapy policy in Benha locality.
Material & methods
Nosocomial Gram positive and negative isolates from different clinical specimens collected from in and out patient at the microbiology lab in Benha University Hospitals from August 2011 till July 2012. The isolates were cultured on relevant enriched and selective media, according to the type of the specimen. Nosocomial infection was defined as any infection that occurred more than 48 hours after admission of the patient to hospital. Any patient who had an infection on admission and had not recovered from that episode the day of the survey and any inpatient who had been hospitalized for fewer than three days was not considered a nosocomial infection case.
(4) All other inpatients who, on the day of the survey, had signs of infection or were identified as infection cases by the ward doctor were considered to be suffering from a nosocomial infection. (5) Gram positive isolates were further subcultured on mannitol salt agar and bile aesculin azide agar for identification of S. aureus and Enteroccoci respectively. All isolates were identified by conventional methods (Gram stain, biochemical reactions by conventional methods), and subjected to antimicrobial susceptibility testing using manual Kirby Bauer disc diffusion method. All isolates were further identified and tested for susceptibility (MIC) by the Sensititre microbiology System. Gram negative bacilli were screened for different resistant mechanisms (ESBL, AmpC, and MBL) by using different phenotypic confirmatory tests (ESBL screening, ESBL and AmpC detection test, Imp, Imp + EDTA combined disc test). 1-Automated identification & antimicrobial susceptibility testing: 0.5 Mcfarland turbidity standards were prepared from all resistant nosocomial strains. Sensititre autoinoculator was used to deliver inoculum in multiples of 50 microliters to the 96-well Sensititre plate. Test results were automatically transferred to data management system for processing, interpretation, and reporting. Sensititre autoreader was used to read both identification and susceptibility plates to maximize consistency. Identification plates included panels for Gram negative rods and Gram positive cocci identification (GNID and GPID). Automated MIC based antimicrobial susceptibility testing was done by GramPositive and Gram-Negative MIC Plates. Complete antimicrobial selection, including gatifloxacin and linezolid, eliminates costs associated with additional off-line test procedures. A new gram positive MIC plate contains FDA-cleared broth D-Test, along with cefoxitin screen and daptomycin to eliminate all offline testing was used.
Antibiotic sensitivity testing was done using the standard disc diffusion method according to CLSI guidelines.
(7) The following discs were used: For gram negative isolates: Amikacin, ampicillin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, cefoxitin, cefotetan, ceftriaxone, ceftazidime, cefuroxime, cefpodoxime, ciprofloxacin, gentamicin, gatifloxacin, imipenem, meropenem, pipracillin, pipracillin/tazobactam, nitrofurantion, ticarcillin/clavulanic acid, tobramycin, trimethoprim-sulfamethoxazole, Ceftazidime/Clavulanic Acid, Cefotaxime/Clavulanic Acid (Bio-Rad, Marnes -La -Coquette, France). ESBL was considered diagnosed by the results of included 3rd generation cephalosprins MICs, and by a decrease of > 3 doubling dilutions in an MIC for either cefotaxime or ceftazidime tested in combination with 4 µg/ml clavulanic acid, versus its MIC when tested alone. For gram positive isolates: Ampicillin, ceftriaxone, ciprofloxacin, clindamycin, erythromycin, gatifloxacin, gentamicin, levofloxacin, oxacillin, cefoxitin, penicillin, rifampicin, tetracycline, vancomycin, trimethoprim-sulfamethoxazole, daptomycin (BioRad, Marnes -La-Coquette, France).
2-Phenotypic (diffusion based) techniques:
1. ESBL screening by double disc diffusion test: as recommended by CLSI, (2011), the inhibition zone diameters around cefotaxime (CTX, 30 ug), ceftazidime (CAZ, 30 ug) & cefepime (FEP, 30 ug) discs with & without clavulanic acid (CA,10 ug) were compared after 16 to 18 hours of incubation in air at 35°C. A five mm or more increase in the inhibition zone diameter of either CTX, CAZ, or FEP discs in the presence of Clavulanic acid (CA) compared to the inhibition zone diameter around CTX, CAZ, or FEP alone, respectively was considered to be a positive result for ESBL production. 2. Imipenem (IMP)-EDTA combined disc test: Two (10 μg) imipenem discs (BIO-Rad, Marnes-la-Coquette, France) were placed on the plate, and appropriate amounts of 10 μL of EDTA solution were added to one of them to obtain the desired concentration of (750 μg). The inhibition zones of imipenem and imipenem-EDTA discs were compared after 16 to 18 hours of incubation in air at 35°C. A seven mm or more increase in inhibition zone diameter around imipenem and EDTA disc compared to the inhibition zone diameter around the imipenem disc alone, was considered to be a positive result for metallo-betalactamase (MBL) production. (8) 3. ESBL and AmpC Detection Set (D68C system): For ESBL positive strains, AmpC (derepressed / hyperproduced and plasmid mediated) positive strains, and co-production of AmpC and ESBL enzymes. (9) Four discs were placed on the plate in the. Each disc is represented by the following: A= Cefpodoxime 10 ug (CPD10) B= CPD10+ESBL inhibitor (clavulanic 1ug) C= CPD10+AmpC inhibitor (cloxacillin 500 ug) D= CPD10+ESBL and AmpC inhibitor (clavulanic 1ug and cloxacillin 500 ug) Interpretation: Organism was considered only ESBL producers when ZB -ZA and ZD -ZC ≥ 5mm and the differences of each of ZB and ZD and ZA and ZC are < 4mm. regarding that Z is referring to the zone diameter of the tested disc. On the other hand, organism would be only AmpC producer when ZD -ZB and ZC -ZA ≥ 5mm and the differences of each of ZA and ZB and ZC -ZD are < 4 mm. The organism was considered positive for both ESBL and AmpC when ZD -ZC ≥ 5mm and the difference of ZA and ZB is < 4mm. The organism was considered negative for both ESBL and AmpC when All zones differ by ≤ 2 mm. Those Enterobacteriaceae remaining resistant to cefpodoxime irrespective of clavulanate and cloxacillin may have an ESBL or AmpC plus impermeability or may have a carbapenemase. These strains deserve reference investigation.
RESULTS
A total of 205 nosocomial specimens were cultured and yielded 89 gram negative and 35 gram positive isolates. In our study we only included the nosocomial gram negative isolates resistant to 3 rd generation cephalosporins (54) and the gram positive isolates which were resistant to vancomycin ± methicillin (20) to be tested by Sensititre for identification and susceptibility. Eleven isolates showed an inhibition zone diameters around the discs containing imipenem+EDTA that were 7 mm or more greater than the inhibition zone diameters around the discs containing imipenem alone which denote that they produce metallo betalactamases (MBL). 
Discussion
Nosocomial infections are a major challenge to patient safety. It is estimated that in 2002, a total of 1.7 million hospital-acquired infections occurred (4.5 per 100 admissions), and almost 99,000 deaths resulted from or were associated with a hospital-acquired infections, making hospital-acquired infections the sixth leading cause of death in the United States ; similar data have been reported from Europe. The estimated costs to the U.S. health care budget are $5 billion to $10 billion annually. Approximately one third or more of hospital-acquired infections are preventable. 
it was found that the most common pathogens (monomicrobial) were Staphylococcus aureus (14.0%), coagulase-negative staphylococci (CoNS) (12.6%), Klebsiella spp. (12.0%), and Acinetobacter spp. (11.4%). We observed a high rate of Klebsiella infection (45.2%) in neonatal ICU followed by E. coli (14.6%), Staphylococcus aureus (13.4%) and CoNS (9.7%). This was against the results of Monsef and Eghbalian (2010) as they found that the most common microorganisms were E. coli (66.7%), Klebsiella spp. (10.5%), followed by CoNS and Staphylococcus aureus. (12) Also, the results of Yalaz et al. (2006) in which the isolated bacteria were CoNS (31.3%), Staphylococcus aureus (13%) and Klebsiella Pneumonia (10.5%) in descending order. (13) As regard the type of sample, Klebsiella and CoNS were the most frequently isolated pathogens from blood, each representing (69.4%) and (38.7%) respectively. El Kholy et al. (2003) found that Enterobacter spp. and CoNS were the frequently isolated pathogens from blood cultures. (14) In our study we collected 205 nosocomial samples, 74 were tested by Sensititre instrument for identification and susceptibility testing, of which 54 were gram negative and 20 were gram positive. They were collected from ICU, surgery, dialysis and internal medicine units.
In our study, all the 18 klebsiella spp. isolates from blood (14 Klebsiella pneumoniae, 1 Klebsiella oxytoca and 3 klebsiella group 47) were 100% resistant to third generation cephalosporins. Among Klebsiella pneumoniae, 57.2% were imipenem resistant, while 71.4% were meropenem resistant. Two out of 3 klebsiella group 47 strains were resistant to both carbapenems. In a study of blood stream isolates of Klebsiella pneumoniae from hospitals throughout the United States, 27.1% from 483 isolates tested were resistant to third-generation cephalosporins and 10.8% from 452 isolates tested were resistant to carbapenems. (15) Higher rates of resistance were reported from parts of Europe. (16) In our study 7 out of 14 Klebsiella pneumoniae strains and 2 klebsiella group 47 strains recovered from neonatal ICU were resistant to all currently available antibiotics included in our Sensititre panel, which was not including polymyxins. The most recent challenge has been the spread of carbapenemase-producing Enterobacteriaceae. The β-lactamase responsible for this phenotype, known as Klebsiella pneumoniae carbapenemase, or KPC, confers reduced susceptibility to all cephalosporins (including cefepime), monobactams (aztreonam), and the carbapenems. (17) Carbapenemase-producing Enterobacteriaceae have been identified in hospitals in at least 20 states in the United States, as well as in other parts of the world, including South America, Israel, China, and, less commonly, Europe. (17) The genetic relatedness of the strains responsible for outbreaks within and between countries highlights the importance of strict infection control to prevent ongoing dissemination. (18) These β-lactamases are encoded on mobile genetic elements, mostly plasmids and transposons, which probably explains their spread among gram-negative genera. Furthermore, they often coexist with other resistance genes, including the most widespread of the ESBLs (the bla CTX-M-15 gene), aminoglycoside-resistance determinants and plasmid-mediated quinolone-resistance genes (qnrA and qnrB) (Nordmann et al., 2009 ) (17) , thus leaving the physician with few therapeutic options. Klebsiella pneumoniae strains that were resistant to all currently available antibiotics, including the polymyxins, had been reported. (16) Also of greatest concern were reports of infections caused by organisms that were resistant to all currently available antibiotics, including the polymyxins.
(19)
Regarding our study, gram-negative organisms predominate in hospital-acquired pneumonia, particularly Klebsiella spp., Enterobacter spp., Pseudomonas aeruginosa, and Acinetobacter baumannii in descending order of frequency. On the contrary in the study of Gaynes and Edwards (2005), (20) gram-negative organisms that predominate in hospital-acquired pneumonia were Pseudomonas aeruginosa, Acinetobacter baumannii, and then Enterobacteriaceae. In the present study gram negative bacteria were responsible for about 26.4% of hospital acquired infections, and these bacteria predominate in septicemia (51.8%) and ventilatorassociated pneumonia (25.9%). Data from the U.S. National Healthcare Safety Network indicate that gram-negative bacteria were responsible for more than 30% of hospitalacquired infections, and these bacteria predominate in cases of ventilator-associated pneumonia (47%) and urinary tract infections (45%). (15) In ICUs in the United States, gram-negative bacteria account for about 70% of these types of infections and similar data were reported from other parts of the world. (20) The present study augmented these data, as we found that the rate of gram-negative bacterial infections in ICUs was 76.3%.
In Europe, 26.4% of 679 Pseudomonas aeruginosa isolates and 36.8% of 427 Acinetobacter baumannii isolates that caused ventilator-associated pneumonia were resistant to carbapenems (imipenem or meropenem). (15) Similar data had been reported from other parts of the world, with countries such as Greece reporting rates of carbapenem resistance of up to 85% among ICU isolates. (16) In our study one Acinetobacter baumannii strain was recovered from a case of ventilatorassociated pneumonia in surgery unit and was resistant to meropenem, but sensitive to imipenem. Another one strain of Pseudomonas aeruginosa was recovered from sputum of ventilated patient in adult ICU and was resistant to the whole panel of Sensititre. One Klebsiella Oxytoca, one Raoultella terrigena and two Klebsiella Pneumoniae were recovered from sputum samples in ICU and were resistant to meropenem but sensitive to imipenem. Infections caused by gram-negative bacteria have features that are of particular concern. These organisms are highly efficient at up-regulating or acquiring genes that code for mechanisms of antibiotic drug resistance, especially in the presence of antibiotic selection pressure. Furthermore, they have a plethora of resistance mechanisms, often using multiple mechanisms against the same antibiotic or using a single mechanism to affect multiple antibiotics. Compounding the problem of antimicrobial-drug resistance is the immediate threat of a reduction in the discovery and development of new antibiotics. (21) Several factors have contributed to this decline, including the increasing challenges of screening for new compounds, the high capital costs and long time required for drug development, the growing complexity of designing and performing definitive clinical trials, and the concern about reduced drug longevity due to the emergence of resistance.
As a consequence, a perfect storm has been created with regard to these infections; increasing drug resistance in the absence of new drug development. (10) The highest rates of nosocomial gram positive bacterial infections were observed in ICUs in our hospital, which were also the units in which the most severely ill patients were treated and in which the highest mortality rates were observed. Similar findings were found in other studies. (22) We observed that the incidence of nosocomial MRSA among collected Staphylococcus aureus was 24.4%. The results of Albertini et al ., (2002) (23) showed a slightly higher rate. The overall proportion of their MRSA isolates was 38.4%. The results of Randrianirina et al., (2010) from Madagascar were much lower.
(5) In their study, the rate of Staphylococcus aureus isolates resistant to oxacillin was 13.6%.
(5) The prevalence of MRSA varies greatly throughout the world. This variation could be explained on the basis of the different sites and clinical associations, and whether the infection is nosocomial or community-based. All our MRSA isolates were vancomycin, linezolid and quinupristin/dalfopristin susceptible, but only 80% were daptomycin susceptible. On the other hand, surveillance of nosocomial infections at a Saudi Arabian military hospital for a one-year period found that only 98.5% of MRSA were vancomycin susceptible and all CoNS were vancomycin susceptible.
(24) In the present study we recorded 3 cases of MRCONs strains which were also vancomycin and linezolid resistance. These VRCONS strains were recovered from blood cultures in neonatal ICU in low birth weight immunosuppressed neonates receiving vancomycin for approximately one month.
We isolated 3 VRE strains (two Enterococcus faecium and one Enterococcus fecalis) from blood cultures in adult ICU patients. On the contrary, Abdel-Fattah (2005) (24) did not observe resistance to vancomycin among isolated enterococci. As pointed out in an extensive review by Safdar and Maki (2002) there is a remarkable commonality of risk factors for infection and colonization with several nosocomial pathogens such as VRE, MRSA, and ESBL producing gram-negative bacteria. (25) Antibiotic exposure has been consistently identified as a risk factor for VRE positivity. It facilitates VRE transmission by 2 mechanisms: by suppression of normal competing bowel flora providing selective advantage for VRE, and by increasing concentration of VRE in stool of previously colonized patients rendering them more contagious.
(26) VRE colonization has been associated with multiple classes of antibiotics including glycopeptides, second and third generation of cephalosporins and other antibiotics with prominent anti-anaerobic activity.
(26) The association of use of vancomycin with VRE remains controversial as several studies showed no effect. (27) Enterobacteriaceae isolates were resistant to extended-spectrum cephalosporins as a consequence of ESBL and/or AmpC production and/or carbapenemase production. The diffusion based methods used in our study were unable to differentiate between chromosomally and plasmid-borne AmpC genes. The presence of these resistance mechanisms was also associated with co-resistance to other classes of antibiotics, including the very commonly prescribed ciprofloxacin, for which only 3 of every 10 nosocomial gram negative isolates remain susceptible. This high level of ciprofloxacin resistance rules out the use of ciprofloxacin as empirical treatment when invasive infections due to these pathogens are suspected. We also found a high rate of resistance to penicillins, beta-lactam/beta-lactamase inhibitor combinations, first and second generation cephalosporins and trimethoprim/sulphamethoxazole. Therefore, cheap antibiotics such as amoxicillin, tetracycline and trimethoprim/ sulphamethoxazole are now of limited benefit in the treatment of infections. These results were probably due to overuse and misuse of broadspectrum antibiotics. Although our relatively limited sample size, uncommon forms of resistance were detected among uncommon pathogens that is difficult, if possible, to be identified by conventional methods without the use of automation. For example, the isolation of Raoultella terrigena strain from one of our sputum samples. It was resistant to all currently available antibiotics, but only sensitive to imipenem. The name Raoultella is proposed as a genus name for species of Klebsiella of cluster II. It was identified as an ESBL producer and this was consistent with the results of Peterson et al., (2008) who documented the appearance of multi-resistant strains among clinical Klebsiella isolates, especially those producing ESBLs.
(28) Also we identified 3 strains of Klebsiella group 47, isolated from blood cultures of neonatal ICU cases. One was identified as an only ESBL producer, and the other 2 strains were resistant to the whole panel of Sensititre antimicrobial susceptibility testing, including imipenem and meropenem and both were identified as positive MBL producers using our imipenem-EDTA combined discs test. Klebsiella group 47 represents a single new species in the genus Klebsiella for which the name Klebsiella ornithinolytica is proposed.
(29) Now it is considered as a species of Klebsiella of cluster II.
We isolated a strain of Aeromonas hydrophila subsp. hydrophila from post operative brain abscess pus after removal of a benign tumor in surgery unit. It was highly resistant to the whole panel of sensititer antimicrobial susceptibility testing including imipenem and meropenem and was identified as ESBL producer in our ESBL and AmpC detection kit. Ye et al., (2010) (31) found that Aeromonas caviae GN07160 isolated from a pneumonia patient, which was resistant to a broad spectrum of beta-lactam antibiotics, harbored a new plasmid-mediated AmpC beta-lactamase. Genes encoding MOX-4, CTX-M-3 and TEM-1 β-lactamases have been detected simultaneously in their A. caviae isolate.
Warren and his colleagues (32) in 2000 isolated a member of the Enterobacteriaceae identified as Kluyvera cryocrescens by the MicroScan Gram-Negative Combo 13 panel caused an outbreak of nosocomial infections in four patients (pneumonia, n = 2; urinary tract infection, n = 1; wound infection, n = 1) and urinary tract colonization in one patient. The antibiotic susceptibility testing revealed the presence of ESBL resistance. They concluded that Kluyvera cryocrescens appears to be a new opportunistic pathogen that can serve as a source of ESBL resistance in the hospital. The same finding was found in our study as we recovered a strain of ESBL producer Kluyvera cryocrescens from hysterectomy wound infection. It was resistant to almost the whole panel of Sensititre antimicrobial susceptibility testing including meropenem, but the strain was only sensitive to imipenem. According to diffusion based techniques, the rate of resistance to the 3rd generation cephalosporins among the 89 nosocomial gram negative isolates was as follows: for extended spectrum beta-lactamases 50 isolates (56.1%), for AmpC resistance 25 isolates (28.1%), and for carbapenem resistance 11 isolates (12.3%), and regarding comparison of the rate of detection of resistance mechanisms, between Sensititre and diffusion based techniques used in this research, it was noticed that there was a suitable agreement between the results of Sensititre and phenotypic detection regarding ESBL and carbapenem resistance. However, results of Sensititre showed much higher number of AmpC, in comparison with diffusion based detection. This may point to that the reliance on only cefoxitin resistance by MIC testing is not a guarantee of establishing a diagnosis of AmpC, as screening by cefoxitin resistance alone may give many false positive results, and other factors may cause cefoxitin resistance without AmpC production, like in case of porin deficiency. In a study conducted by Polsfuss et al., (2011), (33) Cefoxitin was assessed as primary screening marker. The sensitivity of cefoxitin for the detection of AmpC production was 97.4, but the specificity was only 78.7. The discrepancy that was discovered in our results regarding AmpC detection may necessitate the confirmation of AmpC resistance by at least on phenotypic method, without complete reliance on the automated MIC results regarding this pattern of resistance.
Conclusion:
A relatively high rate of resistance was found in our nosocomial isolates. Regarding Gram negative isolates, the highest resistance mechanisms were ESBL, followed by AmpC and carbapenem resistance, especially among Klebsiella pneumoniae isolates. Also, from our results, it was highly evident that there was a high endemicity of MRSA and VRE among our Gram positive cocci nosocomial isolates.
There was a suitable agreement between the results of Sensititre and diffusion based detection regarding ESBL and carbapenem resistance. However, results of Sensititre showed much higher number of AmpC, in comparison with diffusion based detection. This may necessitate the confirmation of AmpC resistance by at least on phenotypic method, without complete reliance on the automated MIC results.
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